AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat

Research output: Contribution to journalArticlepeer-review

415 Scopus citations

Fingerprint

Dive into the research topics of 'AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds